[1]林艳艳,闫朝光,蔡新生△,等.癌症“行气败乱”病机探讨*[J].陕西中医,2018,(11):1620-1622，1633.
　Lin Yanyan,Yan Chaoguang,Cai Xinsheng,et al.The “Xing-Qi disorder”theory of cancer[J].,2018,(11):1620-1622，1633.
点击复制

癌症“行气败乱”病机探讨*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2018年11期
页码:
1620-1622，1633
栏目:
学术探讨
出版日期:
2018-12-31

文章信息/Info

Title:
The “Xing-Qi disorder”theory of cancer
文章编号:
10.3969/j.issn.1000-7369.2018.11.038
作者:
林艳艳1; 闫朝光1; 蔡新生1△; 邓海滨2; 徐振晔2
1.山东中医药大学附属潍坊市中医院肿瘤中心(潍坊 261000), 2.上海中医药大学附属龙华医院肿瘤科(上海 200030）
Author(s):
Lin Yanyan;  Yan Chaoguang;  Cai Xinsheng;  et al.
Cancer Center of Weifang Traditional Chinese Medicine Hospital, Shandong University of Traditional Chinese Medicine(Weifang 261000)
关键词:
癌/中医药疗法 @行气败乱中医病因和病机
Keywords:
Cancer /traditionalChinese medicine therapy@ Xing-Qi disorderEtiological factors and pathogenesis
分类号:
R73
文献标志码:
A
摘要:
癌症的行气败乱病机是我们通过“《内经》理论指导下基于中国癌症发病大数据癌症病因病机研究”得出的新的中医癌症病机，即在人体脏腑功能虚弱的基础上，长期感受四时不正之气，造成机体阴阳不和、五脏功能失调、五行生克制化失衡，最终导致“行气败乱”。癌症是行气败乱的结果，也是形气失调、形不化气的一种病理状态。所以癌症的治疗就是通过“散者收之、终者始之”而纠正阴阳失调、五行败乱而重建人体阴阳五行平衡。本文从行气概念的出处、行气败乱与疾病的关系、癌症行气败乱病机的内涵和意义等方面阐述癌症行气败乱病机的核心内容，为理解和运用该病机防治癌症提供参考。
Abstract:
The “Xing-Qi disorder”theory of cancer is a new TCM cancer pathogenesis based on the study of big data on cancer etiology and pathogenesis in China under the guidance of "the Internal Classic" theory. That is, on the basis of the weak function of the body's viscera, abnormal qi in four seasons recepted for a long time result in the imbalance of Yin and Yang in the body, the dysfunction of the five zang organs, the unbalance of the five elements, and eventually leads to the " Xing-Qi disorder ". Cancer is not only the result of " Xing-Qi disorder ", but also pathological condition of the disorder of form and qi.So,cancer is treated througth correcting unbanlance of Yin and Yang and disorder of five lines,and rebuilding the balance of Yin and Yang in the body. The core content of cancer's Xing-Qi disorder pathogenesis is demonstrated from the aspects of the origin of the concept of qi, the relationship between Xing-Qi disorder and disease, the connotation and significance of Xing-Qi disorder pathogenesis of cancer, providing references for understanding and applying this pathogenesis to prevent and cure cancer.

参考文献/References:

［1］ Lai K, Tang S, Schena F, et al. IgA nephropathy[J]. Nature Reviews Disease Primers, 2016, 2:16001.
［2］Pozzi C.Treatment of IgA nephropathy［J］.J Nephrol,2016，29(1):21-25．
［3］王海燕.肾脏病学［M］. 2版 .北京：人民卫生出版社,1987:714.
［4］Camilla R, Suzuki H, Daprà V, et al. Oxidative stress and galactose-deficient iga1 as markers of progression in IgA nephropathy[J]. Clin J Am Soc Nephrol, 2011, 6(8):1903-1911.
［5］Lin X, Ding J, Zhu L, et al. Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy [J]. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, 24(11):3372.
［6］Gharavi A, Moldoveanu Z, Wyatt R, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy[J]. Journal of the American Society of Nephrology, 2008, 19(5):1008-1014.
［7］王景福,邹建洲,丁小强,等.IgA肾病86例临床与病理分析[J].中国临床医学,2004,11(4)：515-517.
［8］Nair R, Walker P D. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA?[J]. Kidney International, 2006, 69(8):1455-1458.
［9］刘志红, 黎磊石. 葡萄球菌肠毒素诱发的IgA肾病模型[J]. 中华肾脏病杂志, 1989，5(1):6-10.
［10］聂镜江, 刘志红, 黎磊石. 空肠弯曲杆菌诱发大鼠IgA肾病—肠道感染诱发IgA肾病的作用探讨[J]. 医学研究生学报, 1990，3(4):328-331.
［11］韩昌松, 张磊, 金晓明. IgA肾病小鼠模型中氧化应激标志物的检测分析[J]. 哈尔滨医科大学学报, 2012, 46(4):354-356.
［12］金晓明, 张磊, 史炯, 等. 三种实验性IgA肾病模型的比较[J].中华肾脏病杂志,2007, 23(2):115-120.
［13］Sharmin S, Shimizu Y, Hagiwara M, et al. Staphylococcus aureus antigens induce IgA-type glomerulonephritis in Balb/c mice [J]. Journal of Nephrology, 2004, 17(4):504-511.
［14］Yamamoto C，Suzuki S，Kimura H，et al.Experimental nephropathy induced by Haemophilus parainfluenzae antigens[J].Nephron,2002,90(3):327-330.
［15］Jessen R, Emancipator S, Jacobs G, et al. Experimental IgA-IgG nephropathy induced by a viral respiratory pathogen. Dependence on antigen form and immune status[J]. Laboratory Investigation, 1992, 67(3):379-386.
［16］Rifai A, Small PA,Teague PO, et al.Experimenta1 IgA nephropathy［J］.J Exp Med，1979，150:1161-1173.
［17］Isaacs K, Miller F, Lane B. Experimental model for IgA nephropathy[J]. Clinical Immunology & Immunopathology, 1981, 20(3):419-426.
［18］贺敏敏, 董晨, 李俊霞.IgA肾病小鼠模型的建立与鉴定[J].徐州医学院学报,2010, 30(3):151-154.
［19］汤颖, 娄探奇, 成彩联,等. 实验性IgA肾病模型的改进[J]. 中山大学学报:医学科学版, 2006, 27(2):184-187.
［20］朱世乐，章友康. 肝脏的清除功能对聚合IgA在肾脏沉积的影响[J]. 中华肾脏病杂志, 1989，5(1):2-5.
［21］张静, 李静, 桑晓红,等. 运用两种BSA剂量建立IgA肾病大鼠模型观察[J]. 中国中西医结合肾病杂志, 2013, 14(1):13-16.
［22］张静, 张艳, 孙明慧,等. IgA大鼠肾组织中TGF-β_1的表达与肾损害关联性研究[J]. 中国中西医结合肾病杂志, 2016, 17(10):854-857.
［23］陆慧瑜, 张巧玲, 蒋小云,等. IgA肾病大鼠模型的建立[J]. 中国误诊学杂志, 2011, 11(6):1264-1267.
［24］王丽娜, 李静, 刘健,等. 大鼠慢性牙周炎与IgA肾病复合模型血清中MMP-3的表达及意义[J]. 口腔医学研究, 2013，29(11):995-998.
［25］王三合, 康晓玲, 樊平,等. 益肾方对IgA肾病细胞因子表达的实验研究[J]. 陕西中医, 2016, 37(10):1428-1430.
［26］ Rifai A, Mannik M. Clearance of circulating IgA immune complexes is mediated by a specific receptor on Kupffer cells in mice[J]. Journal of Experimental Medicine, 1984, 160(1):125-137.
［27］ Bogers W M, Stad R K, Janssen D J, et al. Kupffer cell depletion in vivo results in clearance of large-sized IgA aggregates in rats by liver endothelial cells [J]. Clinical & Experimental Immunology, 2010, 85(1):128-136.
［28］章友康, 王海燕. 肝脏与IgA肾病的关系及其机制的探讨[J]. 北京大学学报：医学版, 1988，34(4)：257-260,326.
［29］Gormly A, Smith P, Seymour A, et al. IgA glomerular deposits in experimental cirrhosis. Am. J. Pathol[J]. American Journal of Pathology, 1981, 104(1):50-54.
［30］汪春莲, 游宇, 卢放根,等. LPS诱导鼠肝脏和腹腔巨噬细胞TLR4表达和肝损伤的动态分析[J]. 中国现代医学杂志, 2006, 16(11):1657-1660.
［31］Imai H, Nakamoto Y, Asakura K, et al. Spontaneous glomerular IgA deposition in ddY mice: an animal model of IgA nephritis[J]. Kidney International, 1985, 27(5):756.
［32］Suzuki H, Suzuki Y, Yamanaka T, et al. Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23 [J]. Journal of the American Society of Nephrology Jasn, 2005, 16(5):1289.
［33］Miyawaki S. Enhanced production of glomerular extracellular matrix in a new mouse strain of high serum IgA ddY mice [J]. Kidney International, 1996, 50(6):1946-1957.
［34］Miyawaki S. Enhanced production of glomerular extracellular matrix in a new mouse strain of high serum IgA ddY mice[J]. Kidney International, 1996, 50(6):1946-1957.
［35］Okazaki K, Suzuki Y, Otsuji M, et al. Development of a model of early-onset IgA nephropathy[J]. Journal of the American Society of Nephrology Jasn, 2012, 23(8):1364.
［36］Jiang X, Lv Y Q, Zhang J N, et al. Mycoplasma penetrans infection is a potential cause of immunoglobulin A nephropathy: a new animal model[J]. Journal of Nephrology, 2013, 26(3):470.
［37］Suzuki Y, Tomino Y. Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: insights from animal models[J]. Seminars in Nephrology, 2008, 28(1):66-77.
［38］Aw V, Daha M, Eversschouten J, et al. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: evidence for the bone marrow as the source of mesangial IgA [J]. American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation, 1988, 12(5):410.
［39］佐楠, 姚丽, 王力宁,等. 一个骨髓移植方法建立的小鼠IgA肾病模型[J]. 中国现代医学杂志, 2012, 22(29):40-44.
［40］Zheng F, Kundu G, Zhang Z, et al. Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice[J]. Nature Medicine, 1999, 5(9):1018-1025.
［41］彭佑铭. IgA肾病治疗的思考[J]. 中华肾病研究电子杂志, 2016, 5(5):195-198.
［42］Beck L, Bomback A, Choi M, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis[J]. American Journal of Kidney Diseases, 2013, 62(3):403-441.
［43］廖莹, 何永成. 免疫球蛋白A肾病免疫抑制治疗研究进展[J]. 深圳中西医结合杂志, 2016, 26(10):195-198.
［44］Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy[J]. New England Journal of Medicine, 2015, 373(23):2225-2236.
［45］王夏青, 黄晶晶, 谢永祥,等. 史伟教授治疗IgA肾病经验[J]. 中国中西医结合肾病杂志, 2017, 18(6):529-530.
［46］吉勤, 达鸿雁, 李红帅. 中医辨证治疗IgA肾病疗效观察[J]. 云南中医学院学报, 2011, 34(2):32-35.
［47］李四平. 探讨中医“从咽论治”治疗IgA肾病的效果[J]. 深圳中西医结合杂志, 2015, 25(15):60-62.
［48］王丽彦, 刘娜, 张佩青. 张佩青治疗伴有扁桃体异常IgA肾病经验[J]. 上海中医药杂志, 2008, 42(6):10-11.
［49］王俊, 孙伟. 孙伟教授从咽、虚、瘀论治IgA肾病病案举隅[J]. 中医药导报, 2015，22(11):99-101.
［50］潘静, 陈仁铭. 二半汤治疗IgA肾病大鼠的实验研究[J]. 中华中医药学刊, 2016，35(1):39-42.
［51］任燕. 大黄中药灌肠治疗慢性肾功能衰竭的作用机制研究[J]. 中国处方药, 2015, 13(8):18-19.
［52］王军涛. 参芪地黄汤联合四物汤治疗IgA肾病的临床观察[J]. 临床医药文献电子杂志, 2016, 3(4):598-599.
［53］李洁, 俞东容, 陈洪宇,等. 益肾活血祛风湿联合西药治疗IgA肾病远期疗效的临床研究[J]. 中国中西医结合杂志, 2017, 37(1):28-33.

备注/Memo

备注/Memo:
*上海市教育委员会科研创新计划项目（2017-01-07-00-10-E00064）
更新日期/Last Update: 2018-11-30